Trial Profile
Comparative Effects of Moxonidine and Bisoprolol on Bone Metabolism, Vascular and Cellular Markers of Aging, Blood Pressure in Hypertensive Postmenopausal Women (COMPASS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Moxonidine (Primary) ; Bisoprolol
- Indications Hypertension; Metabolic bone diseases
- Focus Biomarker; Pharmacodynamics
- Acronyms COMPASS
- 14 Apr 2021 Results assessing the effect of moxonidine versus bisoprolol on cellular senescence processes in postmenopausal women with arterial hypertension, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension.
- 27 Jul 2018 Status changed from active, no longer recruiting to completed.
- 28 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 May 2018.